Novanta

Novanta, Inc. engages in the provision of core technology solutions to healthcare and advanced industrial original equipment manufacturers. It operates through the following segments: Photonics, Vision, and Precision Motion. The Photonics segment designs, manufactures, and markets photonics-based solutions, including laser scanning and laser beam delivery, CO2 laser, continuous wave and ultrafast laser, and optical light engine products. The Vision segment offers a range of medical grade technologies, including medical insufflators, pumps and related disposables, surgical displays and operating room integration technologies, optical data collection and machine vision technologies, radio frequency identification technologies, thermal printers, spectrometry technologies, and embedded touch screen solutions. The Precision Motion segment includes optical encoders, precision motor and motion control technology, air bearing spindles, and precision machined components to customers. The company was founded in 1968 and is headquartered in Bedford, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Novanta achieves record-breaking 2022 results, eyes growth opportunities

Novanta's strong financial performance in 2022, driven by record sales and profitability, positions the company for continued success.
While facing challenges such as margin pressures and operational disruptions, Novanta's strategic strengths in medical markets and growth opportunities in new product development pave the way for future growth.
With a focus on efficiency, innovation, and market diversification, Novanta is poised to capitalize on growth prospects in 2023 and beyond.
Overall, Novanta's robust performance, strategic initiatives, and financial stability underscore its resilience and potential for sustained growth in the coming years.

Novanta excels in Q1 with strong medical market growth

Novanta's Q1 performance showcased robust revenue growth, particularly in medical markets and North America. The company's strategic focus on new products and margin expansion positions it well for future success despite challenges in certain regions and segments.

Novanta excels in Q2 2023, eyes growth amid market challenges

Novanta's Q2 performance was robust, driven by strong sales in medical markets and strategic growth initiatives.
Challenges include declines in microelectronics and China market, but opportunities lie in new product launches and recovery expectations.
The company's focus on innovation, backlog reduction, and margin expansion positions it well for future growth.
Overall, Novanta exceeded expectations for margins and profits, with a positive outlook for 2024.

Novanta reports solid Q3 performance, eyes new product supercycle

Novanta delivered a strong Q3 performance, exceeding expectations in margins, profit, and cash flow.
The company remains confident in its long-term outlook, focusing on innovation and upcoming product launches.
Despite short-term challenges, Novanta is committed to executing its growth strategy and expanding gross margins.

Novanta reports record revenue in 2023, eyes growth in medical markets

Novanta delivered a solid performance in 2023, achieving record revenue, gross margin expansion, and profit despite market challenges.
The company's focus on new product launches, intelligent subsystems, and growth in medical solutions segment positions it for continued success in 2024.
Challenges from the macroeconomic environment and product ramp downs need to be addressed to ensure sustained growth and profitability.
Opportunities from acquisitions, new product launches, and revenue streams in medical markets offer avenues for future growth and cash flow.

Novanta reports solid Q2 performance, eyes growth through new products

Novanta's Q2 2024 earnings call showcased strong financial performance and strategic priorities for growth.
While facing challenges in certain markets, the company's focus on new products and margin expansion bodes well for the future.
Analysts are keen on revenue drivers, margin expansion, and segment performance as key areas of interest.

Novanta reports solid Q3 earnings, eyes growth amidst short-term challenges

Novanta's Q3 2024 performance reflects steady revenue growth and improved profitability, supported by strong bookings and new product revenue confirmations.
While facing short-term challenges in Q4 2024, the company remains optimistic about robust business growth in 2025, emphasizing new product launches and margin expansion.
Guidance for Q4 2024 and full year 2024 indicates a strategic focus on organic growth, margin improvement, and acquisitions to drive long-term value creation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novanta (NOVT) delivered earnings and revenue surprises of 5.00% and 0.69%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Novanta (NOVT) Q3 Earnings and Revenues Beat Estimates

Shares of Novanta (NASDAQ:NOVT) rose 0.8% in pre-market trading after the company reported Q3 results. Quarterly Results Earnings per share were down 20.75% over the past year to $0.42, which beat the estimate of $0.39.

Recap: Novanta Q3 Earnings

BEDFORD, Mass.--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (the “Company”), a trusted technology partner to medical and advanced technology equipment manufacturers, today reported financial results for the third quarter 2020. Financial Highlights Three Months Ended   (In millions, except per share amounts) October 2,     September 27,     2020     2019   GAAP               Revenue $ 142.9     $ 154.1   Operating Income $ 11.9     $ 12.8   Consolidated Net Income $ 8.3     $ 8.9   Diluted EPS

Novanta Announces Financial Results for the Third Quarter 2020

Novanta (NOVT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Novanta (NOVT) Q3 Earnings Expected to Decline

BEDFORD, Mass.--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that Matthijs Glastra, Chief Executive Officer, and Robert Buckley, Chief Financial Officer, are scheduled to present at the Baird Global Industrial Conference, which is being held virtually, on Wednesday, November 11, 2020. About Novanta Novanta is a leading global supplier of core technology solutions that give m

Novanta to Present at the Baird Global Industrial Conference on Wednesday, November 11, 2020

BEDFORD, Mass.--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (the “Company”), a trusted technology partner to medical and advanced technology equipment manufacturers, will release its third quarter 2020 results on Tuesday, November 10, 2020. The Company will host a conference call on Tuesday, November 10, 2020 at 10:00 a.m. ET to discuss these results. To access the call, please dial (888) 346-3959 prior to the scheduled conference call time. Alternatively, the conference call can be accessed o

Novanta Inc. Schedules Earnings Release and Conference Call for Tuesday, November 10, 2020

Joint

LaZBoy

Medpace Holdings

Top Ranked Momentum Stocks to Buy for August 28th

BEDFORD, Mass.--(BUSINESS WIRE)--Novanta Inc.

Novanta to Present at the Baird Global Healthcare Conference on Wednesday, September 9, 2020

Novanta, Inc. (NOVT) CEO Matthijs Glastra on Q2 2020 Results - Earnings Call Transcript

Novanta Announces Financial Results for the Second Quarter 2020

BEDFORD, Mass.--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (the “Company”), a trusted technology partner to medical and advanced technology equipment manufacturers, will release its second quarter 2020 results on Thursday, August 6, 2020. The Company will host a conference call on Thursday, August 6, 2020 at 10:00 a.m. ET to discuss these results. To access the call, please dial (888) 346-3959 prior to the scheduled conference call time. Alternatively, the conference call can be accessed onli

Novanta Inc. Schedules Earnings Release and Conference Call for Thursday, August 6, 2020

BEDFORD, Mass.--(BUSINESS WIRE)--Novanta Inc. (NASDAQ: NOVT) (the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that Matthijs Glastra, Chief Executive Officer, and Robert Buckley, Chief Financial Officer, are scheduled to present at the CJS Securities 20th Annual New Ideas Summer Conference on Tuesday, July 14, 2020, which is being held virtually. About Novanta Novanta is a leading global supplier of core technology solution

Novanta to Present at the CJS Securities 20th Annual New Ideas Summer Conference on Tuesday, July 14, 2020

Novanta, Inc. (NOVT) CEO Matthijs Glastra on Q1 2020 Results - Earnings Call Transcript

Novanta (NOVT) delivered earnings and revenue surprises of 59.38% and 9.17%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Novanta (NOVT) Q1 Earnings and Revenues Surpass Estimates

Shares of Novanta (NASDAQ:NOVT) were unchanged at $87.91 after the company reported Q1 results.

Recap: Novanta Q1 Earnings

Adient

SINA

SiteOne Landscape Supply

Trade Desk

Figuring out toxic stocks and abandoning them at the right time is the key to shield your portfolio from big losses.

Sell These Toxic Stocks to Avoid Portfolio Bleeding

Novanta Inc. (NOVT) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.

Moving Average Crossover Alert: Novanta

Novanta Inc. (NOVT) CEO Matthijs Glastra on Q4 2019 Results - Earnings Call Transcript

Novanta (NOVT) delivered earnings and revenue surprises of 1.85% and 1.61%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Novanta (NOVT) Beats Q4 Earnings and Revenue Estimates

Earnings Preview: Novanta (NOVT) Q4 Earnings Expected to Decline

Novanta, Inc.: A Better Odds-On Capital-Gain Alternative To Intuitive Surgical

Domino's Pizza

Exact Sciences

Neurocrine Biosciences

Netflix

Here's your proof for taking a long-term approach to investing.

The Five Best Stocks of the Past Decade

Novanta Inc. Buy-Ranked For Near Cap-Gains By Market-Makers

Broadcom

Universal Display

Tucows

One familiar name tops the list, but the others may surprise you.

The 5 Best Tech Stocks of the Decade

Novanta, Inc. (NOVT) CEO Matthijs Glastra on Q3 2019 Results - Earnings Call Transcript

News for Novanta Stock (NOVT)